RXRX Form 4: Dean Y. Li Issued 1,961 Class A Shares as Director Pay

Rhea-AI Filing Summary

Dean Y. Li, a director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,961 shares of Class A common stock on 10/01/2025 at a reported price of $0 under the company’s Outside Director Compensation Policy. After the issuance, Mr. Li directly beneficially owns 1,238,528 shares. The filing also discloses indirect holdings: 1,422,048 shares held by the Dean Y. Li Revocable Trust, 136,981 shares held by the Dean Y. Li GRAT, and 421,000 shares held by the Dean Y. Li 2021 Family Trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Positive

• 1,961 shares issued as compensation under the company’s Outside Director Compensation Policy
• 1,238,528 shares held directly by the reporting person following the transaction, indicating substantial insider ownership

Negative

• None.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Li Dean Y

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	1,961	$0.00	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,238,528 shares (Direct); Class A Common Stock — 1,422,048 shares (Indirect, By Dean Y. Li Revocable Trust)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Li Dean Y

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/01/2025		A(1)		1,961	A	$0	1,238,528	D
Class A Common Stock								1,422,048	I	By Dean Y. Li Revocable Trust
Class A Common Stock								136,981	I	By Dean Y. Li GRAT
Class A Common Stock								421,000	I	By Dean Y. Li 2021 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Dean Y. Li report on Form 4 for RXRX?

The Form 4 reports an acquisition of 1,961 Class A shares on 10/01/2025 issued as director compensation.

How many RXRX shares does Dean Y. Li directly own after the transaction?

After the reported issuance, Dean Y. Li directly beneficially owns 1,238,528 shares of Class A common stock.

Does the filing disclose any indirect holdings for Dean Y. Li?

Yes. Indirect holdings disclosed are 1,422,048 shares in the Dean Y. Li Revocable Trust, 136,981 shares in the Dean Y. Li GRAT, and 421,000 shares in the Dean Y. Li 2021 Family Trust.

At what price were the shares reported as issued?

The reported price for the 1,961 shares is $0, reflecting issuance as compensation under the Outside Director Compensation Policy.

Who signed the Form 4 filing for Dean Y. Li?

The Form 4 was signed by /s/ Jonathan Golightly, attorney-in-fact on 10/03/2025.